Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

Maria M. Posada, PhD, Bridget L. Morse, PharmD, PhD, P. Kellie Turner, PharmD, PhD, Palaniappan Kulanthaivel, PhD, Stephen D. Hall, PhD, and Gemma L. Dickinson, PhD

Abstract
Abemaciclib, a selective inhibitor of cyclin-dependent kinases 4 and 6, is metabolized mainly by cytochrome P450 (CYP)3A4. Clinical studies were performed to assess the impact of strong inhibitor (clarithromycin) and inducer (rifampin) on the exposure of abemaciclib and active metabolites. A physiologically based pharmacokinetic (PBPK) model incorporating the metabolites was developed to predict the effect of other strong and moderate CYP3A4 inhibitors and inducers. Clarithromycin increased the area under the plasma concentration-time curve (AUC) of abemaciclib and potency-adjusted unbound active species 3.4-fold and 2.5-fold, respectively. Rifampin decreased corresponding exposures 95% and 77%, respectively. These changes influenced the fraction metabolized via CYP3A4 in the model. An absolute bioavailability study informed the hepatic and gastric availability. In vitro data and a human radiolabel study determined the fraction and rate of formation of the active metabolites as well as absorption-related parameters. The predicted AUC ratios of potency-adjusted unbound active species with rifampin and clarithromycin were within 0.7- and 1.25-fold of those observed. The PBPK model predicted 3.78- and 7.15-fold increases in the AUC of the potency-adjusted unbound active species with strong CYP3A4 inhibitors itraconazole and ketoconazole, respectively; and 1.62- and 2.37-fold increases with the concomitant use of moderate CYP3A4 inhibitors verapamil and diltiazem, respectively. The model predicted modafinil, bosentan, and efavirenz would decrease the AUC of the potency-adjusted unbound active species by 29%, 42%, and 52%, respectively. The current PBPK model, which considers changes in unbound potency-adjusted active species, can be used to inform dosing recommendations when abemaciclib is coadministered with CYP3A4 perpetrators.

Keywords
drug interaction, abemaciclib, PBPK, CYP3A4, cyclin-dependent kinases 4 and 6, active metabolites

Abemaciclib is an oral cyclin-dependent kinase (CDK) 4 and 6 inhibitor approved for the treatment of hormone receptor–positive, human epidermal growth factor 2–negative advanced or metastatic breast cancer.1–3 The pharmacokinetics of abemaciclib has been characterized in patients and in healthy subjects, with no significant differences between groups.4 Following oral administration, abemaciclib is almost completely absorbed with a time of observed maximum plasma concentration of about 6 to 8 hours.1,5 Abemaciclib is highly bound to plasma proteins, with a fraction unbound in plasma (fu) of 0.0557. Abemaciclib is extensively distributed to tissues, with a systemic volume of distribution at steady state (Vdss) estimated to be 724 L in the absolute bioavailability study. The mean half-life and systemic clearance (CL) of abemaciclib are 29.3 hours and 24 L/h, respectively.6 Following oral administration of a 200-mg dose, the oral bioavailability of abemaciclib is 45%.6

In vitro and human disposition studies have demonstrated that abemaciclib is extensively metabolized via cytochrome P450 (CYP)3A4, but not CYP3A5, in liver to multiple active metabolites.5 These oxidative metabolites are present in significant concentrations in plasma and accounted for approximately 45% of total plasma radioactivity in the human mass balance study.5 Metabolites M2 and M20 are formed from abemaciclib by CYP3A4, and metabolite M18 can be formed by CYP3A4 from either M2 or M20.5 The active metabolites are either eliminated unchanged in bile or further metabolized by CYP3A4 or via sulfate conjugation and eliminated via biliary excretion.5 Clinical drug interaction studies with the CYP3A4 inhibitor clarithromycin...
and inducer rifampin demonstrated the extensive involvement of CYP3A4 metabolism of abemaciclib. Because the patient population for abemaciclib may include individuals taking other medications that can be inhibitors or inducers of CYP3A4, the primary objective of this study was to predict the pharmacokinetics (PK) of a single dose of abemaciclib and its active metabolites (M2, M18, and M20) in the presence of known moderate and strong CYP3A4 inhibitors and inducers using physiologically based pharmacokinetic (PBPK) modeling.

Methods
Clinical Studies With Abemaciclib
All clinical studies used for modeling were approved by the respective institutional review boards or independent ethics committees, and all subjects who participated in the studies provided written informed consent. The studies were conducted in accordance with the principles of the Declaration of Helsinki and consistent with good clinical practices. A description of the clinical studies can be found in the supplemental information.

Simulation Strategy
A scheme of the overall simulation strategy is shown in Figure 1A. Briefly, multiple models were developed and/or verified including models for abemaciclib and its 3 active metabolites, and the CYP3A4 inducers (efavirenz, modafinil, bosentan, and rifampicin) and inhibitors (ketoconazole, itraconazole, clarithromycin, diltiazem, and verapamil). The abemaciclib and metabolites models were built using both physicochemical and biological in vitro data as well as data from the absolute bioavailability study and the human radiolabel disposition study. The fractions formed and metabolized via CYP3A4 for abemaciclib and metabolites models were furthered optimized using the results from the rifampicin and clarithromycin interaction studies.

Software
Simcyp version 14 (Sheffield, UK) was used to develop and/or verify the pharmacokinetics of abemaciclib, 3 active metabolites (M2, M18, and M20), ketoconazole, itraconazole, clarithromycin, diltiazem verapamil, rifampin, efavirenz, bosentan, and modafinil. These models were used to simulate and predict drug-drug interactions between 200 mg abemaciclib and the various inhibitors and inducers, including those that have not been studied in human clinical trials.

Input Data
The input parameters to the PBPK models are summarized in Table 1.

Simulation Assumptions
Absorption. The fraction of 200 mg abemaciclib absorbed (Fa) from the intestine after an oral dose was calculated using equation 1:

\[
Fa = 1 - \left( \frac{\% \text{ of parent in feces}}{\% \text{ of dose recovered}} \right)
\]  

(1)

where the percentage of parent in feces, determined in the \(^{14}\text{C}\) study, was 6.76 and the percentage of dose quantified was 75.4% (total radioactivity recovery was 84%). Therefore, the Fa was determined to be 0.91. The Fa and the absorption rate constant (Table 1) were input into the first-order absorption model within Simcyp.

Distribution. A full PBPK model was selected for the parent compound, and minimal PBPK models were selected for the metabolites. The tissue composition–based model (method 2) implemented in Simcyp as proposed by Rodgers et al\(^{7-10}\) was selected to predict the volume of distribution of abemaciclib at steady state. The tissue-to-plasma partition coefficient scalar was adjusted to 2.5 to match the observed Vdss, calculated by noncompartmental analysis from intravenous (IV) data in the ABA study.\(^{6}\) The Vdss of the 3 active metabolites was estimated manually, while clearance was kept fixed (see elimination section), based on the assumption that volume is the primary factor driving the metabolites’ peak plasma concentration (Cmax).

First-Pass Hepatic Extraction. The fraction of a 200-mg oral dose of abemaciclib escaping first-pass metabolism in the liver (F_H) was calculated according to equations 2, 3, and 4, by first calculating the IV blood clearance (CL_{B,iv}):

\[
CL_{B,iv} = \frac{CL_{IV}}{B:P}
\]  

(2)

where CL_{IV} was the IV plasma clearance (24 L/h) and B:P was the blood to plasma concentration ratio (0.84). The CL_{B,iv} was used to calculate the hepatic extraction ratio (E_H):

\[
E_H = \frac{CL_{B,iv}}{Q}
\]  

(3)

where Q was the hepatic blood flow, assumed to be 80 L/h.\(^{11}\) Finally, F_H was calculated from E_H:

\[
F_H = 1 - E_H
\]  

(4)

resulting in a calculated F_H of 0.64.

First-Pass Gut Extraction. The fraction of a 200-mg oral dose of abemaciclib escaping first-pass metabolism
Figure 1. A, Simulation strategy. B, Proposed disposition scheme for abemaciclib and active metabolites after a 200-mg dose. *FG was set to 1 for a 50-mg dose of abemaciclib. ADME indicates absorption, distribution, metabolism, and excretion; CL, clearance; Fa, fraction absorbed; Fe, fraction eliminated; FG, fraction escaping first-pass metabolism in the gut; Fh, fraction escaping first-pass metabolism in the liver; fm, fraction metabolized by CYP3A4; fu, fraction unbound; ka, absorption rate constant; pKa, acid dissociation constant; PopPK, population pharmacokinetics; Vd, volume of distribution.
### Table 1. PBPK Input Parameters for Abemaciclib and Active Metabolites in Healthy Volunteers

#### Abemaciclib

| Parameter | Value | Source |
|-----------|-------|--------|
| Molecular weight (g/mol) | 506.6 | Measured |
| LogP | 3.36 | Measured |
| pKa 1 (basic) | 7.95 | Measured |
| pKa 2 (basic) | 4.48 | Measured |
| Blood-to-plasma ratio | 0.84 | Measured in vitro |
| fu plasma | 0.0357 | Measured in vitro [18] |
| $k_{h}^{-1}$ (%CV) | 0.2 (60) | PopPK analysis |
| $F_{a}$ | 0.91 | Estimated from mass balance study |
| $h_{Peff}$ (10^{-4} cm/s) | 2.46 | Predicted from HBD and PSA (Simcyp v14) |
| fu,gut | 0.7 | Manually fitted to obtain $F_{G} = 0.75$ match observed $F = 0.45$ |
| Qgut (L/h) | 10.1 | Predicted (Simcyp) |
| Polar surface area (Å²) | 71.4 | Predicted, in-house QSAR model |
| Number of hydrogen bond donors | 1 | Predicted, in-house QSAR model |
| $V_{dss}$ (L/kg) | 8.93 | ABA study (IV administration) |
| $CL_{systemic}$ (L/h) | 24 | ABA study (IV administration) |
| $CL_{renal}$ (L/h) | 1.0 | Estimated from mass balance study |
| $CL_{int}$ CYP3A4 p1 ($\mu$L/min/pmol isoform) | 0.634 | Back-calculated from IV CL of ABA Study and fm values from 14C study using the retrograde model in Simcyp |
| $CL_{int}$ CYP3A4 p2 ($\mu$L/min/pmol isoform) | 0.117 | |
| $CL_{int}$ CYP3A4 p3 ($\mu$L/min/pmol isoform) | 0.576 | |
| $CL_{int}$ HLM ($\mu$L/min/mg protein) | 9.733 | |

#### M2

| Parameter | Value | Source |
|-----------|-------|--------|
| Molecular weight (g/mol) | 478.55 | Predicted (Prism) |
| LogP | 3.66 | Predicted (Chemaxon) |
| pKa (basic) | 9.19 | Predicted (Chemaxon) |
| fu plasma | 0.081 | Measured in vitro |
| Blood-to-plasma ratio | 0.836 | Predicted (Simcyp) |
| $V_{d}$ (L/kg) minimal PBPK model | 12.1 | Fitted manually to approximate $C_{max}$ |
| $CL_{int}$ CYP3A4 ($\mu$L/min/pmol isoform) | 0.487 | Fitted manually based on interaction with rifampin |
| $CL_{int}$ HLM ($\mu$L/min/mg protein) | 100 | |

#### M20

| Parameter | Value | Source |
|-----------|-------|--------|
| Molecular weight (g/mol) | 522.6 | Predicted (Prism) |
| LogP | 2.78 | Predicted (Chemaxon) |
| pKa (basic) | 8.37 | Predicted (Chemaxon) |
| Blood-to-plasma ratio | 0.67 | Predicted (Simcyp) |
| fu plasma | 0.021 | Measured |
| $V_{d}$ (L/kg) minimal PBPK model | 1.24 | Fitted manually to approximate $C_{max}$ |
| $CL_{int}$ CYP3A4 ($\mu$L/min/pmol isoform) | 0.444 | Fitted manually based on interaction with rifampin |
| $CL_{int}$ HLM ($\mu$L/min/mg protein) | 21.369 | Fitted manually based on interaction with rifampin |

#### M18

| Parameter | Value | Source |
|-----------|-------|--------|
| Molecular weight (g/mol) | 494.5 | Predicted (Prism) |
| LogP | 2.35 | Predicted (Chemaxon) |
| pKa (basic) | 9.19 | Predicted (Chemaxon) |
| Blood-to-plasma ratio | 0.664 | Predicted (Simcyp) |
| fu plasma | 0.034 | Measured in vitro |
| $V_{d}$ (L/kg) minimal PBPK model | 2.5 | Fitted manually to approximate $C_{max}$ |
| $CL_{int}$ CYP3A4 ($\mu$L/min/pmol isoform) | 0.197 | Fitted manually based on interaction with rifampin |
| $CL_{int}$ HLM ($\mu$L/min/mg protein) | 423.210 | Fitted manually based on interaction with rifampin |

ABA indicates absolute bioavailability study; $CL_{int}$, intrinsic clearance; LogP, calculated octanol/water partition coefficient; $C_{max}$, maximum plasma concentration; $F_{a}$, absolute bioavailability; $F_{G}$, fraction absorbed; $F_{C}$, fraction of the dose that escapes first-pass gut metabolism; fm, fraction metabolized; fu, fraction unbound; fu,gut, fraction unbound of drug in the enterocyte; fu plasma, fraction unbound in plasma; HBD, hydrogen bond donor; HLM, human liver microsomes; $h_{Peff}$, predicted human effective permeability; IV, intravenous; $k_{h}$, absorption rate constant; pKa, acid dissociation constant; PBPK, physiologically based pharmacokinetics; PopPK, population pharmacokinetic studies; PSA, polar surface area; Qgut, hybrid term that includes villous blood flow and permeability through the enterocyte; QSAR, quantitative structure-activity relationship; $V_{dss}$, volume of distribution at steady state.

*aRenal clearance estimated as 4% of systemic clearance based on radioactivity recovery in urine in the mass balance study (NCT01913314).*

*b1 is the CYP3A4-mediated clearance pathway that forms M2.*

*b2 is the CYP3A4-mediated clearance pathway that forms M20.*

*b3 is the CYP3A4-mediated clearance pathway that forms metabolites not included in this model.*

*bCYP3A4-mediated clearance pathway that forms M18.*
in the gut (F_G), was calculated according to equation 5:

\[
F_G = \frac{F}{F_H \times F_a}
\]  

(5)

where the absolute bioavailability (F) was 0.45, F_H was 0.64, and F_a was 0.91, giving an F_G value of approximately 0.77.

It should be noted that when abemaciclib is dosed at 50 mg, the dose-normalized abemaciclib exposure is higher than when it is dosed at 200 mg. The difference is thought to represent a lower gut extraction (and higher F_G) at 50 mg than at 200 mg rather than a difference in the intrinsic clearance, absorption, or any other parameter. This possibility is further considered in the Discussion.

**Metabolism and Elimination.** In order to calculate the fraction of abemaciclib metabolized by CYP3A4 (f_m), equation 6, previously described, \(^1\) was rearranged to equation 7:

\[
AUC_{R} = \frac{1}{A \times f_m + (1 - f_m) AUC_c}
\]  

(6)

\[
f_m = \frac{AUC_c}{AUC_R} - 1
\]  

(7)

where the area under the concentration time curve (AUC) ratio of inhibited to uninhibited abemaciclib (AUC_R) was 3.37 in the clarithromycin interaction study, and A describes the proportion of CYP3A4 intrinsic clearance in the liver that was inhibited by 500 mg of clarithromycin given orally twice daily for 5 days before the administration of abemaciclib. The parameter A was calculated for clarithromycin using static modeling with IV midazolam as the substrate drug (according to the observed 3.5-fold increase in midazolam AUC extrapolated to infinity \(^1\)).

The percentage of the oral abemaciclib dose recovered in feces of the parent compound and the 6 metabolites are listed in Table S2. M1, M2, M20, and M22 are primary metabolites. M21 is a secondary metabolite formed from M20. M18 is a secondary metabolite that could be formed from either M2 or M20. In order to calculate the fraction of metabolites formed, the percentage of analytes recovered in feces was adjusted to 100, assuming the proportion of each metabolite remains constant (Table S2). The fraction of M2 formed from the parent compound was calculated by summing the percentage of M2 and M18 present in feces and dividing by 100. The fraction of M20 formed was calculated by summing the percentages of M20 and M21 recovered in feces and dividing by 100.

In the human mass balance study, 4% of the radioactivity was excreted in urine, and for modeling purposes it was assumed to be parent compound (cold profiling of urine suggests parent is the predominant species in urine). Initial estimates of the systemic clearances of M2 and M20 (CL_met) were calculated from equation 8:

\[
CL_{met} = f_{m,p-m} \times CL_{parent} \times \frac{AUC_{0-\infty parent}}{AUC_{0-\infty Met}}
\]  

(8)

where f_m,p-m was the fraction of the parent forming each of the metabolites (calculated as described above), CL_parent was the observed systemic (IV) clearance of the parent compound, AUC_{0-\infty Met} was the observed area under the plasma concentration-time curve of the metabolite M2 or M20, and AUC_{0-\infty parent} was the observed area under the plasma concentration-time curve of the parent (from the rifampin interaction study \(^5\)). M18 can be formed from M2 or M20; however, for modeling purposes it was assumed that it is formed solely from M2 (supported by the observation that M2 is the major route of metabolism). Hence, the systemic clearance of the secondary metabolite M18 (CL-M18) was calculated according to equation 9, \(^1\)

\[
CL_{M18} = f_{m,2-18} \times CL_{M2} \times \frac{AUC_{0-\infty M2}}{AUC_{0-\infty M18}}
\]  

(9)

where f_{m,2-18} is the fraction of M2 forming M18, CL_{M2} was the systemic clearance of M2 calculated from equation 8, AUC_{0-\infty M2} was the observed area under the plasma concentration-time curve of M2 (from rifampin interaction study), and AUC_{0-\infty M18} was the observed area under the plasma concentration-time curve of M18 (from the human mass balance study).

The fraction of M20 metabolized via CYP3A4 (0.74) was determined by manual fitting to be within 0.8- and 1.25-fold of the observed AUC_{0-\infty} in the human mass balance study and the observed AUC_{0-\infty} ratio of for M20 in the rifampin interaction study. \(^5\) The fraction of M2 metabolized via CYP3A4 (0.4) was similarly fitted to match the AUC_{0-\infty} and the AUC_{0-\infty} ratios of M2 and M18 in the rifampin interaction study. The fraction of M18 metabolized via CYP3A4 (0.06) was fitted to match the observed AUC_{0-\infty} and the AUC_{0-\infty} ratio of M18 in the rifampin interaction study. The CL_{int} values of M2, M18, and M20 were manually optimized within Simcyp to match the observed AUC_{0-\infty} of each of the metabolites in both arms of the rifampin interaction study. Renal clearance (1 L/h) was estimated as 4% of systemic clearance, based on the recovered radioactivity in urine in the mass balance study.

**Simulation Design.** The simulations were all performed with the Simcyp Healthy Volunteer population
aged 40 to 65 years, and 80% female to approximate to the clarithromycin and rifampin clinical interaction study populations. All simulations were performed under fasted conditions with 100 virtual individuals (10 trials of 10 individuals each).

**Inhibition Simulations.** The predictions of the effect of CYP3A4 inhibition by clarithromycin (500 mg twice daily (BID)), diltiazem (120 mg 3 times daily) and its n-desmethyl metabolite, and verapamil (120 mg 3 times daily) were performed using standard Simcyp v14 library files with modifications described below. Inhibitors were dosed orally for 12 days, and on day 7 a dose of 200 mg of abemaciclib was given 2 hours after the first dose of the inhibitor.

**Modifications to Inhibitor Files.** The ketoconazole and itraconazole files available in Simcyp version 14 predicted AUC ratios for abemaciclib of 7- and 3.8-fold, respectively. This is significantly lower than would be predicted AUC ratios for abemaciclib of 7- and 3.8-fold, itraconazole files available in Simcyp version 14 pre-

The ketoconazole and itraconazole are known strong inhibitors of CYP3A4, and itraconazole is expected, given that ketoconazole and itraconazole are expected to interact with abemaciclib. This is significantly lower than would be predicted AUC ratios for abemaciclib of 7- and 3.8-fold, itraconazole files available in Simcyp version 14 pre-

The ketoconazole and itraconazole files available in Simcyp version 14 predicted AUC ratios for abemaciclib of 7- and 3.8-fold, respectively. This is significantly lower than would be predicted AUC ratios for abemaciclib of 7- and 3.8-fold, itraconazole files available in Simcyp version 14 pre-

**Induction Simulations.** The predictions of the effect of CYP3A4 induction by rifampin (600 mg once daily (QD)), modafinil (200 mg QD for 7 days and then 400 mg QD), efavirenz (600 mg QD), bosentan (125 mg BID), were performed using either standard Simcyp library files (efavirenz and rifampin) with a slight modification to the rifampin file as described below or custom files described below (modafinil and bosentan). The prediction of the effect of efavirenz (600 mg QD) was performed using the Simcyp v16 library file, implemented in Simcyp v14. The inducers were dosed orally for 12 days, and on day 7, a 200-mg dose of abemaciclib was given concurrently with the dose of the inducer, except for the interaction with modafinil, where modafinil was dosed QD for 40 days, and abemaciclib was given on day 27 to reproduce dosing schedules from several published clinical trials.

**Modifications to Simcyp Inducer Files.** The inhibition of CYP3A4 by rifampin was removed from the model to better replicate the observed interaction with abemaciclib given that rifampin is not a CYP3A4 inhibitor. The prediction was verified against the observed interaction with known CYP3A4 substrates (see the Model Verification section).

**Inducer Files for Bosentan and Modafinil.** The bosentan PBPK model was developed using physicochemical and biological in vitro data and published in vivo data. The model included hepatic and nonhepatic (target-mediated) clearances as observed at therapeutic bosentan plasma concentrations and autoinduction of CYP3A4-mediated bosentan clearance. These assumptions were verified using bosentan single- and multiple-dose data. Active uptake into the liver via organic anion–transporting polypeptides (OATPs) was considered in the model to reproduce in vivo hepatic clearance of bosentan as well as in the calculation of in vitro induction parameters (maximal induction fold and 50% of the maximal induction unbound concentration). Because the model was able to accurately predict the autoinduction of bosentan with regard to CYP3A4 metabolism in both the gut and liver, no induction of OATPs by bosentan was necessary in the model. The modafinil induction file was built based on a published model, with minor changes to the input parameters. The input parameters for bosentan and modafinil are shown in Table S3.

Because the clarithromycin CYP3A4-mediated interaction was overpredicted, the competitive inhibition of CYP3A4 by clarithromycin was removed, leaving time-dependent inhibition only as reported in the literature. This resulted in improved predictions compared with observed interactions with abemaciclib. The prediction of the clarithromycin-midazolam interaction was also acceptable and is described in the Model Verification section.
Abemaciclib Active Species Calculations

Calculations for the prediction of the AUC ratio for the active species are shown in equation 10:

\[
\frac{AUC \text{ ratio active species}}{AUC \text{ parent}} = \frac{AUC_{\text{parent In}} + AUC_{\text{M2 In}} + AUC_{\text{M20 In}} + AUC_{\text{M18 In}}}{AUC_{\text{parent}} + AUC_{\text{M2}} + AUC_{\text{M20}} + AUC_{\text{M18}}} \tag{10}
\]

where AUC has the units nanomole-hour per liter, and the subscript “In” indicates the AUC of the parent or metabolite when coadministered with the inhibitor or inducer.

To account for protein-binding and potency differences among the 4 active analytes, the AUCs of parent and metabolites were adjusted according to equations 11 and 12, respectively:

\[
AUC_{\text{parent adjusted}} = AUC_{\text{parent}} \times f_{u \text{ parent}} \tag{11}
\]

where \(f_{u \text{ parent}}\) is the fraction unbound of parent abemaciclib in plasma, and

\[
AUC_{\text{metabolite adjusted}} = AUC_{\text{metabolite}} \times f_{u \text{ metabolite}} \times \frac{IC_{50 \text{ Parent}}}{IC_{50 \text{ Metabolite}}} \tag{12}
\]

where \(f_{u \text{ metabolite}}\) is the fraction unbound of the metabolite(s) in plasma, and half-maximal inhibitory concentration for parent/metabolite represents the in vitro potency for CDK4/cyclin D1 of each analyte. The mean ± SD CDK4/cyclin D1 half-maximal inhibitory concentration values were measured in vitro and are as follows: 1.57 ± 0.6 nmol/L for abemaciclib, 1.24 ± 0.4 nmol/L for M2, 1.46 ± 0.2 nmol/L for M18, and 1.54 ± 0.2 nmol/L for M20.\(^{36}\) The adjusted AUC ratios of active species were then calculated as in equation 10.

Results

Abemaciclib Simulations

The proposed disposition of abemaciclib and active metabolites is shown in Figure 1B. The observed and the model-simulated plasma concentration-time profiles of abemaciclib and its 3 active metabolites M2, M20, and M18 after a 50- and 200-mg dose of abemaciclib are shown in Figure 2 and Figure 3. The model adequately reproduced the observed concentration profiles of abemaciclib and its metabolites in the control arm of the rifampin and clarithromycin studies. The predicted \(C_{\text{max}}\) and \(AUC_{0-\infty}\) values are all within 0.66- and 1.25-fold of the observed values (Table 2).

Interaction Simulations

The observed and the model-predicted plasma concentration-time profiles of abemaciclib and active metabolites M2, M20, and M18 when a 50-mg dose of abemaciclib was coadministered with clarithromycin are shown in Figure 2. The model-predicted concentration-time profiles are consistent with observed abemaciclib and metabolites in the presence of clarithromycin. The \(C_{\text{max}}\) and \(AUC_{0-\infty}\) ratios for the interaction are listed in Table 3. The observed and the model-predicted plasma concentration-time profiles of abemaciclib and its metabolites M2, M20, and M18 when a 200-mg dose of abemaciclib was coadministered with rifampin are shown in Figure 2. The models reproduced the observed concentration-time profiles in the presence of rifampin. These \(C_{\text{max}}\) and \(AUC_{0-\infty}\) ratios for the interaction are also listed in Table 3. Using the criteria published by Guest and collaborators,\(^{37}\) with a \(\Delta\) value of 1.3 based on the percentage coefficient of variation (CV) of abemaciclib AUC after intravenous dosing, the models were acceptable and able to capture the effect of clarithromycin and rifampin on abemaciclib and active metabolites within the appropriate limits (Figure 3).

The predicted \(C_{\text{max}}\) and \(AUC_{0-\infty}\) ratios for a 200-mg dose of abemaciclib and its active metabolites when coadministered with other CYP3A inhibitors and inducers are listed in Table 4. The model predicted 7.11- and 15.7-fold increases in abemaciclib AUC in the presence of strong CYP3A4 inhibitors itraconazole and ketoconazole, respectively; and, 2.27- and 3.90-fold increases with the concomitant use of moderate CYP3A4 inhibitors verapamil and diltiazem, respectively (Table 4). The model predicted AUC ratios of 0.31, 0.32, and 0.54 in abemaciclib AUC in the presence of CYP3A4 inducers efavirenz, bosentan, and modafinil, respectively (Table 4). The predicted AUC ratios for the potency-adjusted unbound active species with diltiazem, verapamil, itraconazole and ketoconazole ranged from 1.62 to 7.15 (Table 4). The predicted AUC ratios for the potency-adjusted unbound active species with efavirenz, bosentan, and modafinil ranged from 0.48 to 0.71 (Table 4).

Model Verification

The abemaciclib PBPK model was verified against multiple clinical studies, including studies that were not used in model building (Table S4). All assumptions and conditions used in the inhibition simulations were verified using midazolam as a victim drug. Models of various CYP3A4 inhibitors were qualified by comparing the simulated and observed \(AUC_{0-\infty}\) and \(C_{\text{max}}\) ratios of midazolam in the presence and absence of these inhibitors (Table S5). The models of the strong CYP3A4
inducer, rifampin, qualified by Simcyp. The modafinil PBPK model was qualified by comparing the predicted PK parameters after a single and multiple dose with the observed values. Furthermore, the observed AUC and $C_{\text{max}}$ ratios of palbociclib, triazolam, and midazolam in the presence and absence of modafinil are within 0.78- to 1.14-fold of the observed values (Table S7).
Figure 3. Predicted vs observed (A) AUC ratios and (B) Cmax ratios for abemaciclib, M2, M18, and M20 with rifampin and clarithromycin. Open symbols represent the ratios with clarithromycin and solid symbols the ratios with rifampin. Open squares represent abemaciclib + clarithromycin. Open circles represent M2 + clarithromycin. Open diamonds represent M20 + clarithromycin. Open triangles represent M18 + clarithromycin. Closed squares represent abemaciclib + rifampin. Closed circles represent M2 + rifampin. Closed diamonds represent M20 + rifampin. Closed triangles represent M18 + rifampin. The solid black lines represent the lines of unity, the solid gray lines represent the 2-fold limits, and the dotted lines represent the upper and lower limits defined by Guest and collaborators$^{37}$ using a $\Delta_1$ value of 1.3. AUC indicates area under the plasma concentration–time curve; Cmax, peak plasma concentration.

The bosentan model adequately reproduced the reported PK of bosentan after a single 125-mg dose in healthy male volunteers.$^{34}$ The observed over-predicted ratios of AUC$_{0-\tau}$ and Cmax are within 1.06 and 1.25 (Table S6). The model also adequately reproduced the reported CYP3A4 autoinduction in bosentan PK after multiple dosing (125 mg BID for 10 days).$^{34}$ The observed over predicted ratios of AUC$_{0-\tau}$ and Cmax are within 0.97 and 1.12 (Table S6).

Furthermore, the model accurately predicted the gut-specific CYP3A4 autoinduction of bosentan, which can be calculated with data from the Tracleer (bosentan) clinical pharmacology biopharmaceutics review.$^{40}$ Following 5 days of bosentan 125 mg BID in the absence and presence of ketoconazole 200 mg QD. The observed and predicted $F_G$ values for bosentan on day 5 were 0.62 and 0.67. The observed $F_G$ value is calculated from a reported C$_{\text{max}}$ ratio of 1.62 with and without ketoconazole and assuming an $F_G$ of 1.0 in the presence of ketoconazole (calculated using reported data from the Tracleer U.S. Food and Drug Administration clinical pharmacology biopharmaceutics review).$^{40}$ The predicted $F_G$ is calculated by applying a Qgut model to the PBPK model–predicted CYP3A4 gut intrinsic clearance on day 5.$^{31}$ The induction of CYP3A4 by bosentan was additionally verified using midazolam, a well-characterized CYP3A4 substrate. The interactions were simulated using the midazolam model developed and verified by SimcypV14 (Table S7).

Sensitivity Analyses

A sensitivity analysis was conducted to determine the effect of individually changing the $f_m$ by CYP3A4 of abemaciclib (parent), M2, M18, and M20 on the AUC ratio associated with the clarithromycin interaction. A complementary sensitivity analysis was performed to determine the effect of changing individual $f_m$ values on the potency-adjusted unbound AUC ratios of the active species. Figure 4 shows the effect of changing CYP3A4 $f_m$ on the AUC ratio with clarithromycin of the individual species (abemaciclib, M2, M20, and M18) (Figure 4A). As expected, the AUC ratio of parent drug associated with the clarithromycin interaction was sensitive to changes in the $f_m$ of parent drug because of the high dependence on CYP3A4 for elimination. In contrast, the clarithromycin DDI AUC ratios for the active metabolites were insensitive to changes in $f_m$ because the metabolites are not highly dependent on CYP3A4 for elimination. A similar trend was seen for the effect of changing individual $f_m$ values on the potency-adjusted unbound AUC ratios for parent drug and active metabolites (Figure 4B). The predicted AUC ratio (ratio with clarithromycin coadministration to no inhibitor control) for total active species was sensitive to parent drug $f_m$ but not the $f_m$ of the individual metabolites for the reasons described previously. Together, these data indicate that the $f_m$ for parent drug has been accurately estimated because suboptimal values would not reproduce the observed extent of DDI with clarithromycin.

Within the Simcyp framework, the fraction unbound in the gut ($fu,gut$) is employed to set the desirable value of gut wall availability ($F_G$) at given values of membrane permeability and CYP3A4 intrinsic clearance in the Qgut model.$^{42}$ For the abemaciclib PBPK model, the value of $F_G$ for the 50-mg dose was 0.98 and the corresponding $fu,gut$ was 0.008, whereas for the 200-mg abemaciclib model, the $F_G$ was 0.74 and the corresponding $fu,gut$ was 0.7. The boundaries of possible $fu,gut$ values are therefore established by the observed DDIs with clarithromycin and rifampin.
Table 2. Observed Versus Predicted AUC and $C_{\text{max}}$ Values for Abemaciclib, M2, M20, M18, and Total Active Species After an Oral Dose of 50 mg or 200 mg Abemaciclib

| Compound | Parameter | Observed Geometric Mean (%CV) | Predicted Geometric Mean (%CV) | Observed/Predicted |
|----------|-----------|-------------------------------|-------------------------------|--------------------|
|          |           | AUC(0-$\infty$) (ng·h/mL)     | AUC(0-$\infty$) (ng·h/mL)     |                     |
| Abemaciclib |           | 2230 (93)                    | 1461 (50)                     | 1.53               |
|           | $C_{\text{max}}$ (ng/mL) | 70.0 (73)                      | 46 (48)                       | 1.52               |
|           | $T_{\text{max}}$ (h)$^*$ | 4.03 (2-23.78)                  | 3.61 (0.91-35.26)             | 1.12               |
|           | $T_{\text{e}}$ (h)   | 28.8 (12.2-79.2)               | 25.2 (16.13-48.99)            | 1.14               |
| M2 |           | 509 (75)                      | 457 (41)                      | 1.11               |
|           | $C_{\text{max}}$ (ng/mL) | 9.11 (70)                      | 7.78 (40)                     | 1.17               |
|           | $T_{\text{max}}$ (h)$^*$ | 4.00 (1-24.50)                  | 5.93 (1.85-68.55)             | 0.67               |
|           | $T_{\text{e}}$ (h)   | 60.1 (10.8-200)                | 31.25 (21.11-56.13)           | 1.92               |
| M20 |           | 1090 (63)                     | 777 (41)                      | 1.40               |
|           | $C_{\text{max}}$ (ng/mL) | 18.1 (66)                      | 14.0 (21)                     | 1.29               |
|           | $T_{\text{max}}$ (h)$^*$ | 6.00 (2-24.50)                  | 16.08 (4.46-63.51)            | 0.37               |
|           | $T_{\text{e}}$ (h)   | 43.0 (19.7-94.8)               | 25.10 (16.74-49.74)           | 1.71               |
| M18 |           | 196 (176)                     | 152 (48)                      | 1.29               |
|           | $C_{\text{max}}$ (ng/mL) | 3.53 (61)                      | 2.73 (54)                     | 1.29               |
|           | $T_{\text{max}}$ (h)$^*$ | 4.00 (1-74.27)                  | 11.78 (5.67-63.26)            | 0.34               |
|           | $T_{\text{e}}$ (h)   | 38.0 (4.18-151)                | 30.79 (21.08-57.26)           | 1.23               |
| 200 mg abemaciclib (control group rifampin study) | Abemaciclib | 4570 (53)                     | 4449 (50)                     | 1.03               |
|           | AUC(0-$\infty$) (ng·h/mL) | 134 (45)                      | 140 (51)                      | 0.96               |
|           | $C_{\text{max}}$ (ng/mL) | 8.00 (4-24)                     | 3.60 (0.91-35.26)             | 2.22               |
|           | $T_{\text{max}}$ (h)$^*$ | 25.2 (17.6-42.7)                | 25.19 (16.68-48.92)           | 1.00               |
|           | $T_{\text{e}}$ (h)   | 35 (47)                       | 10.08 (30-120)                | 1.96               |
| M2 |           | 1780 (30)                     | 1861 (41)                     | 1.26               |
|           | $C_{\text{max}}$ (ng/mL) | 35 (47)                       | 38 (40)                       | 0.92               |
|           | $T_{\text{max}}$ (h)$^*$ | 6.08 (4-24)                     | 4.98 (1.75-60.66)             | 1.22               |
|           | $T_{\text{e}}$ (h)   | 60.5 (43.1-123)                | 31.11 (21.19-57.21)           | 1.95               |
| M20 |           | 3760 (33)                     | 3112 (41)                     | 1.21               |
|           | $C_{\text{max}}$ (ng/mL) | 63 (32)                       | 63 (22)                       | 1.00               |
|           | $T_{\text{max}}$ (h)$^*$ | 10.00 (4-24)                    | 13.28 (4.31-56.85)            | 0.75               |
|           | $T_{\text{e}}$ (h)   | 35.8 (27.2-58.8)               | 25.10 (16.74-49.49)           | 1.43               |
| M18 |           | 660 (38)                      | 628 (47)                      | 1.05               |
|           | $C_{\text{max}}$ (ng/mL) | 12 (69)                       | 13 (49)                       | 0.92               |
|           | $T_{\text{max}}$ (h)$^*$ | 6.03 (4-24)                     | 10.13 (4.95-53.97)            | 0.60               |
|           | $T_{\text{e}}$ (h)   | 52.5 (30.9-91.8)               | 30.70 (21.14-56.71)           | 1.71               |

AUC(0-$\infty$) indicates area under the concentration-time curve from 0 to infinity; $C_{\text{max}}$, maximal concentration observed; CV, coefficient of variation; $T_{\text{max}}$, time of observed $C_{\text{max}}$; $T_{\text{e}}$, plasma half-life.

$^*$Median (min-max).

Sensitivity analyses were performed to determine the effect of changing FG and fu,gut on the AUC ratio with clarithromycin of abemaciclib and potency-corrected unbound active species. As expected, the AUC ratio of abemaciclib is moderately sensitive to changes in fu,gut and FG over the feasible range, whereas the unbound AUC ratio of active species adjusted for potency is insensitive to changes in fu,gut (Figure 4C and 4D). Misspecification of fu,gut is not expected to significantly influence AUC ratios associated with coadministration of CYP3A4 inhibitors.

**Discussion**

The use of PBPK modeling to support dosing recommendations for DDI scenarios in regulatory submissions and prescribing labels has increased in recent years as exemplified by recent publications.43-45
## Table 3. Predicted and Observed AUC\(_{(0-\infty)}\) and C\(_{\text{max}}\) Ratios for Abemaciclib, M2, M20, M18, and Active Species When Abemaciclib Is Coadministered With Clarithromycin and Rifampin

| Compound | Parameter | Observed Geometric Mean (90%CI) | Predicted Geometric Mean (90%CI) | Observed/Predicted |
|----------|-----------|---------------------------------|----------------------------------|--------------------|
| 50 mg abemaciclib with clarithromycin | | | | |
| Abemaciclib | AUC\(_{(0-\infty)}\) ratio | 3.37 (2.85-3.99) | 3.80 (3.50-4.11) | 0.89 |
| | C\(_{\text{max}}\) ratio | 1.30 (1.10-1.52) | 1.61 (1.56-1.66) | 0.81 |
| M2 | AUC\(_{(0-\infty)}\) ratio | 1.32 (1.14-1.53) | 0.90 (0.85-0.95) | 1.47 |
| | C\(_{\text{max}}\) ratio | 0.33 (0.27-0.40) | 0.33 (0.30-0.37) | 1.00 |
| M20 | AUC\(_{(0-\infty)}\) ratio | 0.94 (0.84-1.06) | 1.32 (1.24-1.41) | 0.71 |
| | C\(_{\text{max}}\) ratio | 0.27 (0.21-0.34) | 0.47 (0.43-0.51) | 0.57 |
| M18 | AUC\(_{(0-\infty)}\) ratio | NC | 0.31 (0.28-0.34) | NC |
| | C\(_{\text{max}}\) ratio | NC | 0.13 (0.11-0.15) | NC |
| Potency-adjusted unbound active species | AUC\(_{(0-\infty)}\) ratio | 2.45 | 2.47 | 0.99 |

| 200 mg abemaciclib with rifampin | | | | |
| Abemaciclib | AUC\(_{(0-\infty)}\) ratio | 0.05 (0.04-0.06) | 0.08 (0.07-0.09) | 0.63 |
| | C\(_{\text{max}}\) ratio | 0.08 (0.07-0.09) | 0.15 (0.13-0.17) | 0.53 |
| M2 | AUC\(_{(0-\infty)}\) ratio | 0.35 (0.32-0.38) | 0.38 (0.35-0.41) | 0.92 |
| | C\(_{\text{max}}\) ratio | 0.96 (0.81-1.13) | 0.84 (0.78-0.90) | 1.14 |
| M20 | AUC\(_{(0-\infty)}\) ratio | 0.20 (0.19-0.22) | 0.20 (0.18-0.22) | 1.00 |
| | C\(_{\text{max}}\) ratio | 0.64 (0.56-0.73) | 0.52 (0.47-0.57) | 1.23 |
| M18 | AUC\(_{(0-\infty)}\) ratio | 1.31 (1.18-1.44) | 1.67 (1.59-1.76) | 0.78 |
| | C\(_{\text{max}}\) ratio | 4.26 (4.24-4.31) | 3.40 (3.18-3.64) | 1.25 |
| Potency-adjusted unbound active species | AUC\(_{(0-\infty)}\) ratio | 0.23 | 0.28 | 0.82 |

AUC\(_{(0-\infty)}\) indicates area under the concentration-time curve from 0 to infinity; C\(_{\text{max}}\), maximal concentration observed; NC, not calculated.

*Concentration values of M18 after administration of clarithromycin were below the limit of quantitation of 1 ng/mL.

Regulatory acceptance of such PBPK-driven recommendations appears to have increased concurrently, as the models become more robust and can simulate ever more complex scenarios.\(^{46,47}\) However, various regulatory authorities have also indicated the need for thorough model qualification and testing.\(^{48,49}\)

Early in the development cycle, the metabolic profile of abemaciclib was understood to include a significant CYP3A4 component. Hence, clinical DDI studies were conducted with clarithromycin and rifampin.\(^5\) In these studies, abemaciclib AUC ratios of 3.4 and 0.05, respectively, and total active species AUC ratios of 2.5 and 0.23, respectively, were observed, indicating that CYP3A4 did indeed play an important role not just in the metabolism of abemaciclib (f\(_m\) = 0.89; Figure 1B) but also in its active metabolites (f\(_m\) = 0.1-0.7; Figure 1B). It would therefore be important to include prescribing recommendations for other types of CYP3A4 perpetrators (ie, strong and moderate) in the drug label. Fortunately, PBPK modeling allows for the efficient use of the vast amount of clinical knowledge gathered over the last 30 years in multiple drug interaction studies and the translation of the in vitro characteristics (ie, induction and inhibition parameters) of several CYP3A4 perpetrators. This is evident by the high number of applications of this type of modeling by academia, regulatory agencies, and industry.\(^{50-55}\) A PBPK modeling approach was used to predict the effect of CYP3A4 inhibitors and inducers that have not been tested with abemaciclib but have been tested in the clinic with well-characterized sensitive CYP3A4 substrates (eg, midazolam, triazolam), for which the used PBPK models have been thoroughly verified. However, in order to have value in accurately predicting CYP3A4-mediated interactions, the model would need to be unusually complex, incorporating first-pass elimination by the gut and liver, 3 metabolites, and multiple routes of elimination of the parent compound and the metabolites (CYP mediated and non–CYP-mediated metabolism and renal elimination).

It was critical to capture both parent and metabolite exposure in the model due to the metabolites having similar potency at CDK4 and CDK6 as the parent. Similar to abemaciclib, each of the metabolites was known to undergo CYP3A4-mediated metabolism. Although inhibition of CYP3A4 would result in a likely increase in exposure to abemaciclib and a decrease in the formation clearance of metabolites, the elimination clearance of the metabolites would also decrease, resulting in a complex disposition scenario whereby the overall effect on the exposure to total active species can only be understood through the use of an integrated...
Table 4. Predicted AUC(0-inf) and Cmax Ratios for Abemaciclib, M2, M20, and M18, and Active Species After Coadministration of 200 mg of Abemaciclib, Moderate and Strong CYP3A4 Inhibitors, and Moderate Inducers, Geometric Mean (90%CI)

| Inhibitor | Compound | AUC (0-inf) Ratio | Cmax Ratio |
|-----------|----------|------------------|------------|
| Diltiazem | Abemaciclib | 3.90 (3.67-4.16) | 1.90 (1.64-2.19) |
|           | M2       | 2.67 (2.39-2.96) | 1.90 (1.64-2.19) |
|           | M20      | 1.04 (1.00-1.08) | 0.61 (0.57-0.66) |
|           | M18      | 0.42 (0.39-0.45) | 0.22 (0.17-0.27) |
|           | Ketoconazole | 0.53 (0.50-0.56) | 0.67 (0.63-0.70) |
|           | Efavirenz | 0.57 (0.53-0.61) | 0.75 (0.72-0.79) |
|           | Modafinil | 0.57 (0.53-0.61) | 0.75 (0.72-0.79) |
|           | Itraconazole | 0.34 (0.31-0.36) | 0.60 (0.56-0.64) |
|           | Verapamil | 0.12 (0.10-0.14) | 0.94 (0.90-0.97) |
|           | Ketoconazole | 2.37 | 1.42 (1.37-1.47) |

*The concentration-time curve from 0 to infinity Cmax, maximal concentration observed.

AUC(0-inf) indicates area under the concentration-time curve from 0 to infinity; Cmax, maximal concentration observed.

aThe interaction was modeled by reducing the CYP3A-mediated clearance by 90%.

bThe interaction was modeled by reducing the CYP3A-mediated clearance to 0.

Clarithromycin is designated as a strong inhibitor of CYP3A based on the observed interaction with sensitive substrate midazolam,13 which demonstrated an AUC ratio of 6.32 (Table S5). However, both itraconazole and ketoconazole are known to more strongly inhibit CYP3A4 in both the gut and liver.20,22,23 Hence, it was important to demonstrate the potential “worst case” interaction ratios that would result when abemaciclib is dosed with stronger inhibitors. Following qualification of all the inhibitor models against midazolam data taken from the literature, the model. Despite the complexity of this task, which involved integrating and reconciling data from multiple studies, high interindividual variability in observed abemaciclib pharmacokinetics, challenges associated with fitting multiple analytes (abemaciclib, M2, M20, and M18), and fitting different dose levels with apparently different absorption characteristics, it was possible to achieve an acceptable and useful match to the observed data. As shown in Figure 2, most of the predicted concentration-time profiles matched the observed median, and all were within the 90% prediction interval (Figure 2), demonstrating that the current parameter set is well justified and based on sound assumptions. Further, the observed versus predicted ratios ranged from 0.92 for the Cmax of M18 after a 200-mg dose, up to 1.53 for the AUC of abemaciclib after a 50-mg dose. Although not perfect, the fit of the model predictions to the observed clinical data can certainly be considered acceptable, given the large variability in observed parameters. For example, the AUC of abemaciclib and its metabolites demonstrated observed CV values ranging from 30% to 176%, depending on the analyte and the dose (Table 2). Similarly, observed CV values for Cmax ranged from 32% to 73%, depending on analyte and dose. Figure 3 displays the observed versus predicted (1) AUC and (2) Cmax ratios for abemaciclib, M2, M18, and M20 when coadministered with clarithromycin or rifampin. The data are within the predictability limits from 2 different methods used to assess the accuracy of the predictions. The first method is the traditional 2-fold measure, and the second is the method introduced by Guest and collaborators,37 in which the limits are narrower when the ratios are close to 1 and approach the 2-fold traditional method with larger ratios. For this work, the variability term was taken from the percentage CV in abemaciclib after intravenous administration, as in the approach taken with the variability in midazolam in the aforementioned publication. Figure S1 displays similar plots with a variability term of 1.65 reflective of the larger variability in AUC and Cmax observed for the active species after oral administration of abemaciclib. As expected, the predicted and observed AUC ratios are also within the successful prediction these wider limits.
interaction with abemaciclib was simulated. The resulting AUC ratios with various moderate to strong inhibitors ranged from 2.27 to 15.7 for the parent alone and from 1.62 to 7.15 for the potency-adjusted unbound total active species (Table 4). Similar differences in the magnitude of the effect of moderate inducers on parent alone compared with total active species demonstrate the importance of considering the total active species. If a dose reduction recommendation were based on the AUC ratio of abemaciclib alone, it could potentially result in patients being under- or overdosed.

This PBPK model encompassed several assumptions. First, in the human absorption, distribution, metabolism, excretion ADME study, 85% of the radioactivity was recovered in feces and urine over 336 hours. Given the low amounts of radioactivity recovered at later time points, only feces samples were pooled (up to 216 hours) and profiled using accelerator mass spectrometry for parent and metabolites. Therefore, in this modeling exercise it was assumed that the percentage of the parent excreted in feces calculated from the profiled samples using Equation 1 would have been the same if measured in the total recovered radioactivity. We believe this assumption holds true even for the capsule and tablet formulations, given the high permeability, high solubility, and fast dissolution in the stomach pH of abemaciclib. Furthermore, the effect of a high-fat and high-calorie meal increased the AUC.

Another assumption was that CYP3A4 $f_m$ of abemaciclib and the metabolites could be determined using the data from the clarithromycin and rifampin interaction studies. The $f_m$ assumptions in the model could be further verified with other studies. Although, the current model is able to reproduce the known interactions with these 2 perpetrators, and the sensitivity analyses show that changes in $f_m$ do not have a high impact on the AUC of the potency-corrected unbound active species.

Another assumption of the model is that the partition of abemaciclib and metabolites into the liver is perfusion rate limited. This holds true because abemaciclib and active metabolites have good permeability and are not substrates of hepatic uptake transporters organic cation transporter 1, organic anion–transporting polypeptide 1B1 or 1B3. Therefore, the changes observed in plasma caused by CYP3A4 perpetrators are expected to reflect the changes inside the liver. Given this, we were able to use the plasma AUC and $C_{\text{max}}$ values for the parent and the metabolites, in the presence and absence of rifampin and clarithromycin, to calculate the fractions formed and eliminated via CYP3A4.

Although abemaciclib in vitro is a substrate of P-glycoprotein and breast cancer resistance protein, these intestinal efflux transporters were not incorporated into the model given the high permeability and solubility and the expected lack of an effect of inhibitors of P-glycoprotein and breast cancer resistance protein on the PK of abemaciclib.

In addition to facilitating an understanding of optimal prescribing in the presence of CYP3A-modulators, the approach taken to building the PBPK model led to a deeper understanding of the mechanisms underlying abemaciclib PK and identified some interesting characteristics. For example, the bioavailability of abemaciclib appears to be different with 50- versus 200-mg doses. This difference is thought to reflect a difference in $F_G$ and was further confirmed with population analyses conducted throughout development. These analyses showed that hepatic intrinsic clearance and absorption were not dependent on dose, whereas $F_G$ was shown to change with dose. Further, no difference in the fraction absorbed was expected between dose levels due to the compound having high predicted human effective jejunal permeability ($2.46 \times 10^{-4}$ cm/s), fast dissolution in the stomach, and a lack of precipitation.

A comparison of AUC-based metabolite:parent ratios (Table S1) between the clarithromycin study conducted at 50 mg and 2 studies conducted at 200 mg (rifampin interaction and ABA studies) reveals approximately 2-fold higher ratios in the 200-mg studies, compared with the 50-mg study. Hence, there was a greater extent of metabolism at 200 mg, and the observed difference in exposure between doses is therefore the result of metabolic differences and not absorption changes.

The absolute bioavailability study informs the value of $F_G$. Although abemaciclib PK and identified some interesting characteristics. For example, the bioavailability of abemaciclib appears to be different with 50- versus 200-mg doses. This difference is thought to reflect a difference in $F_G$ and was further confirmed with population analyses conducted throughout development. These analyses showed that hepatic intrinsic clearance and absorption were not dependent on dose, whereas $F_G$ was shown to change with dose. Further, no difference in the fraction absorbed was expected between dose levels due to the compound having high predicted human effective jejunal permeability ($2.46 \times 10^{-4}$ cm/s), fast dissolution in the stomach, and a lack of precipitation.

The prediction of the DDIs is determined by $f_m$ and $F_G$. Because there is some degree of computational difficulty in identifying the true value of $f_m$ and $F_G$, sensitivity analyses were conducted on these parameters. The absolute bioavailability study informs the value of the product of $F_a$ and $F_G$; however, it does not allow the identification of the individual parameters. Instead, $F_G$ was calculated indirectly by assuming $F_a$ is 0.91 (based on permeability, solubility, and parent drug excreted in feces). As would be expected, altering $F_G$ has the biggest effect on a predicted AUC ratio for abemaciclib but a minimal effect on the total active...
species bound and unbound (Figure 4B). Another sensitivity analysis was conducted to determine the effect of individually changing the CYP3A4 \( f_m \) of abemaciclib (parent), M2, M18, and M20 on the AUC ratio associated with the clarithromycin interaction. As expected (Figure 4), the AUC ratio of parent drug associated with the clarithromycin interaction was sensitive to changes in the \( f_m \) of parent drug because of the high dependence on CYP3A4 for elimination. In contrast, the clarithromycin DDI AUC ratios for the active metabolites were insensitive to changes in \( f_m \) because the metabolites are not highly dependent on CYP3A4 for elimination.

**Conclusions**

In conclusion, a complex PBPK model for abemaciclib and active metabolites was developed and verified. The model output demonstrated the importance of considering total active species when using PBPK to determine dose adjustments for molecules with active metabolites. The current PBPK model, which considers changes in unbound potency-adjusted active species, can be used to inform dosing recommendations to support prescribing practices when abemaciclib is coadministered with inhibitors and inducers of CYP3A4.

**Conflicts of Interest**

M.M.P., B.L.M., P.K.T., S.D.H., and G.L.D. are all employees and shareholders of Eli Lilly and Company; P.K. is a shareholder of Eli Lilly and Company.

**Data Sharing**

Lilly provides access to all individual participant data collected during the trials, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been...
approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data-sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.

References

1. Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740-753.
2. Tate SC, Sykes AK, Kulanthaivel P, et al. A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin Pharmacokinet. 2018;57(3):335-344.
3. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf. Accessed May 10, 2019.
4. Chigutsa E, Sykes KS A, Posada MM, Turner PK. A mechanistic population pharmacokinetic model of abemaciclib and its metabolites and the impact of diarrhea. Paper presented at: American Conference on Pharmacometrics; October 14-19, 2017; Fort Lauderdale, FL.
5. Kulanthaivel P, Mahadevan D, Turner PK, et al. Abstract CT153. Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors. Cancer Res. 2016;76(14 suppl):CT153.
6. Turner K, Chappell J, Kulanthaivel P, Ng WT, Royalty J. Food effect on the pharmacokinetics of 200-mg abemaciclib in healthy subjects. In: Proceedings from the American Association for Cancer Research, April 16-20, 2016, New Orleans, LA. Abstract CT152.
7. Rodgers T, Leaby D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci. 2005;94(6):1259-1276.
8. Rodgers T, Leaby D, Rowland M. Tissue distribution of basic drugs: accounting for enantiomer, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci. 2005;94(6):1237-1248.
9. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95(6):1238-1257.
10. Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918-933.
11. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093-1095.
12. Fahmi OA, Maurer TS, Kish M, et al. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos. 2008;36(8):1698-1708.
13. Quinney SK, Haechner BD, Rhoades MB, et al. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol. 2008;65(1):98-109.
14. Nguyen HQ, Kimoto E, Callegari E, Obach RS. Mechanistic modeling to predict midazolam metabolite exposure from in vitro data. Drug Metab Dispos. 2016;44(5):781-791.
15. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014;95(5):473-476.
16. Liu L, Bello A, Dresser MJ, et al. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol. 2016;56(2):143-151.
17. Guo Y, Luksiri A, Dickinson GL, et al. Quantitative Prediction of CYP3A4- and CYP3A5-mediated drug interactions. Clin Pharmacol Ther. 2019;107:246-256.
18. Chen Y, Cabalu TD, Callegari E, et al. Recommendations for the design of clinical drug-drug interaction studies with itraconazole using a mechanistic physiologically-based pharmacokinetic model. CPT Pharmacomet Syst Pharmacol. 2019;8:685-695.
19. Han B, Mao J, Chien YJ, Hall SD. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos. 2013;41(7):1329-1338.
20. Halama B, Hohmann N, Burhenne J, et al. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93(6):564-571.
21. Galetin A, Gertz M, Houston JB. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol. 2008;4(7):909-922.
22. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antymycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55(5):481-485.
23. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antymycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82(3):511-516.
24. Quinney SK, Zhang X, Luksiri A, et al. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos. 2010;38(2):241-248.
25. Ke A, Barter Z, Rowland-Yeo K, Almond L. Towards a best practice approach in PBPK modeling: case example of developing a unified efavirenz model accounting for induction of CYPs 3A4 and 2B6. CPT Pharmacomet Syst Pharmacol. 2016;5(7):367-376.
26. Almond LM, Mukadam S, Gardner I, et al. Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model. Drug Metab Dispos. 2016;44(6):821-832.
27. Almond LM, Yang J, Jamei M, Tucker GT, Rostami-Hodjegan A. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr Drug Metab. 2009;10(4):420-432.
28. Hoffman JT, Loi C-M, Plotka A, et al. Abstract LB-198. A phase I open-label fixed-sequence two-period crossover study of the effect of multiple doses of modafinil on palbociclib (PD-0332991) pharmacokinetics in healthy volunteers. Cancer Res. 2016;76(14 suppl):LB-198.
29. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther. 2002;71(1):46-56.
30. Rowland A, van Dyk M, Warncken D, et al. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. Br J Clin Pharmacol. 2018;84(3):501-509.
31. Rowland A, Mangoni AA, Hopkins A, Sorich MJ, Rowland A. Optimized cocktail phenotyping study protocol using physiological based pharmacokinetic modeling and in silico assessment of metabolic drug-drug interactions involving modafinil. *Front Pharmacol*. 2016;7:517.

32. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of regapaglron by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. *Basic Clin Pharmacol Toxicol*. 2005;97(4):249-256.

33. Sun Y, Chothe PP, Sager JE, et al. Quantitative prediction of intestinal first-pass drug metabolism. *Clin Pharmacokinet*. 2017;56(12):1499-1511.

34. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. *J Clin Pharmacol*. 2008;48(5):610-618.

35. Burke T, Torres R, McNulty A, et al. Abstract 2830. The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6. *Cancer Res*. 2016;76(14 Suppl):2830.

36. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. *Drug Metab Dispos*. 2017;45(6):692-705.

37. Zineh I, Abernethy D, Hop C, et al. Improving the tools of clinical pharmacology: goals for 2017 and beyond. *Clin Pharmacol Ther*. 2015;97(3):247-262.

38. Dharmaraj J, Rehder E, Heffernan N, et al. Pharmacokinetics of modafinil and armodafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. *Clin Ther*. 2010;32(12):2074-2087.

39. Food and Drug Administration. Label package insert Tracleer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021290s039,209279s005lbl.pdf. Accessed November 7, 2017.

40. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodgjegan A. Prediction of intestinal first-pass drug metabolism. *Curr Drug Metab*. 2007;8(7):676-684.

41. Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Reply to Rostami-Hodgjegan and Tucker 2002. *Hepatology*. 2002;35:1549-1550. Hepatology. 2002;35:1550-1551.

42. Yu Y, Loi CM, Hoffman J, Wang D. Physiologically based pharmacokinetic modeling of palbociclib. *J Clin Pharmacol*. 2017;57(2):173-184.

43. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. *Clin Pharmacol Ther*. 2011;89(2):259-267.

44. Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. *Clin Pharmacol Ther*. 2012;92(1):17-20.

45. Food and Drug Administration. Physiologically based pharmacokinetic analyses—format and content guidance for industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM531207.pdf. Accessed May 10, 2019.

46. European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf. Accessed May 10, 2019.

47. Jones H, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. *Clin Pharmacol Ther*. 2015;97(3):247-262.

48. de Zwart L, Snoeys J, De Jong J, et al. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. *Clin Pharmacol Ther*. 2016;100(5):548-557.

49. Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. *Clin Pharmacol Ther*. 2015;97(3):247-262.

Supplemental Information

Additional supplemental information can be found by clicking the Supplements link in the PDF toolbar or the Supplemental Information section at the end of web-based version of this article.